A risk-benefit assessment of serotonin 5-HT₃ receptor antagonists in antineoplastic therapy-induced emesis

Medicine & Life Sciences

• Serotonin 5-HT3 Receptor Antagonists 84%
• Ondansetron 80%
• dolasetron 80%
• Antiemetics 73%
• Granisetron 68%
• Antineoplastic Agents 59%
• Vomiting 53%
• Risk Assessment 51%
• Tropisetron 45%
• Pharmacokinetics 23%
• Receptors, Serotonin, 5-HT3 20%
• Clinical Trials 20%
• Patient Preference 17%
• Nausea 13%
• Appointments and Schedules 12%
• Randomized Controlled Trials 10%
• Therapeutics 10%
• Costs and Cost Analysis 9%
• Safety 8%
• Pharmaceutical Preparations 6%

Chemical Compounds

• Ondansetron 100%
• Serotonin 5-HT3 Receptor Antagonist 98%
• Dolasetron 96%
• Antineoplastic 80%
• Granisetron 79%
• Antiemetic 77%
• Tropisetron 56%
• Antiemetic Agent 27%
• Pharmacokinetics 23%
• Route of Application 22%
• Safety 13%
• Dose 11%
• Drug 8%